Virtus ETF Advisers LLC Acquires New Shares in Geron Co. (NASDAQ:GERN)

Virtus ETF Advisers LLC acquired a new stake in Geron Co. (NASDAQ:GERN) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 179,012 shares of the biopharmaceutical company’s stock, valued at approximately $252,000. Virtus ETF Advisers LLC owned approximately 0.10% of Geron at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its holdings in Geron by 3.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 1,080,623 shares of the biopharmaceutical company’s stock valued at $1,524,000 after acquiring an additional 31,448 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Geron by 11.0% in the second quarter. Bank of New York Mellon Corp now owns 805,331 shares of the biopharmaceutical company’s stock valued at $1,135,000 after buying an additional 79,827 shares during the last quarter. SG Americas Securities LLC increased its holdings in Geron by 667.9% in the first quarter. SG Americas Securities LLC now owns 433,705 shares of the biopharmaceutical company’s stock valued at $720,000 after buying an additional 377,226 shares during the last quarter. Bienville Capital Management LLC bought a new stake in Geron in the first quarter valued at about $332,000. Finally, Wells Fargo & Company MN increased its holdings in Geron by 38.9% in the second quarter. Wells Fargo & Company MN now owns 128,235 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 35,925 shares during the last quarter. 31.16% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ GERN traded up $0.01 during mid-day trading on Friday, reaching $1.59. The company had a trading volume of 2,347,110 shares, compared to its average volume of 1,161,810. Geron Co. has a twelve month low of $0.95 and a twelve month high of $6.66. The stock has a market capitalization of $297.71 million, a PE ratio of -9.94 and a beta of 2.57. The stock’s 50 day moving average is $1.33 and its 200-day moving average is $1.52.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. Geron had a negative net margin of 5,328.80% and a negative return on equity of 22.33%. The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.20 million. Sell-side analysts forecast that Geron Co. will post -0.43 EPS for the current fiscal year.

GERN has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on Geron in a report on Thursday, August 15th. They issued an “overweight” rating and a $4.00 price objective for the company. BidaskClub raised Geron from a “sell” rating to a “hold” rating in a report on Saturday, August 17th. HC Wainwright initiated coverage on Geron in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $4.00 target price for the company. ValuEngine upgraded Geron from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. Finally, B. Riley lifted their target price on Geron from $3.25 to $4.50 and gave the company a “buy” rating in a research note on Friday, June 28th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $3.55.

About Geron

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Featured Story: What is the definition of a trade war?

Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.